TW202341995A - 用於治療cns相關病症之神經活性類固醇 - Google Patents

用於治療cns相關病症之神經活性類固醇 Download PDF

Info

Publication number
TW202341995A
TW202341995A TW112105363A TW112105363A TW202341995A TW 202341995 A TW202341995 A TW 202341995A TW 112105363 A TW112105363 A TW 112105363A TW 112105363 A TW112105363 A TW 112105363A TW 202341995 A TW202341995 A TW 202341995A
Authority
TW
Taiwan
Prior art keywords
compound
treatment
antidepressant
administered
individual
Prior art date
Application number
TW112105363A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 阿爾方索 雷舍
詹姆士 多赫提
杰佛瑞 馬丁 強納斯
史帝芬 傑 凱恩思
布魯斯 漢丹 剛杜斯
艾米 Ｅ 布洛克
蒂莫西 Ｙ 馬里亞諾
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202341995A publication Critical patent/TW202341995A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112105363A 2022-02-16 2023-02-15 用於治療cns相關病症之神經活性類固醇 TW202341995A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263310581P 2022-02-16 2022-02-16
US63/310,581 2022-02-16
US202263337828P 2022-05-03 2022-05-03
US63/337,828 2022-05-03
US202363482200P 2023-01-30 2023-01-30
US63/482,200 2023-01-30

Publications (1)

Publication Number Publication Date
TW202341995A true TW202341995A (zh) 2023-11-01

Family

ID=85569830

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112105363A TW202341995A (zh) 2022-02-16 2023-02-15 用於治療cns相關病症之神經活性類固醇

Country Status (11)

Country Link
US (1) US20250295674A1 (https=)
EP (1) EP4479032A1 (https=)
JP (1) JP2025508406A (https=)
KR (1) KR20240148425A (https=)
CN (1) CN119072304A (https=)
AU (1) AU2023220976A1 (https=)
CA (1) CA3252357A1 (https=)
IL (1) IL315023A (https=)
MX (1) MX2024009974A (https=)
TW (1) TW202341995A (https=)
WO (1) WO2023158668A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015002252A (es) 2012-08-21 2015-07-21 Sage Therapeutics Inc Metodos para tratar epilepsia o estado de epilepsia.
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AU2022266680A1 (en) * 2021-04-29 2023-11-02 Sage Therapeutics, LLC 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
CN117442618B (zh) * 2023-10-23 2025-11-14 国科大杭州高等研究院 化合物ly2940094在制备治疗中枢神经系统脱髓鞘疾病药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
CA3103421A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CN111454318A (zh) * 2019-01-20 2020-07-28 浙江易众化工有限公司 抗抑郁药物sage-217的晶型及其制备方法
US20230285417A1 (en) 2020-07-20 2023-09-14 Sage Therapeutics, Inc. Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Also Published As

Publication number Publication date
US20250295674A1 (en) 2025-09-25
JP2025508406A (ja) 2025-03-26
IL315023A (en) 2024-10-01
CN119072304A (zh) 2024-12-03
KR20240148425A (ko) 2024-10-11
EP4479032A1 (en) 2024-12-25
MX2024009974A (es) 2024-09-30
AU2023220976A1 (en) 2024-09-05
WO2023158668A1 (en) 2023-08-24
CA3252357A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
TW202341995A (zh) 用於治療cns相關病症之神經活性類固醇
TWI776407B (zh) 激動劑形成之調配物及使用其之方法
US6395788B1 (en) Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprine
CN117959309A (zh) 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN115734785A (zh) (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
TWI826380B (zh) Nk-1 拮抗劑組合物及用於治療抑鬱症之方法
JP2025510913A (ja) 双極性障害の処置のための５－ＭｅＯ－ＤＭＴ
US10278977B2 (en) Methods for treating hypersomnolence
KR20240152410A (ko) 아티카프란트를 포함하는 조성물
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
TW202308653A (zh) 以神經活性類固醇進行治療的方法
WO2024102802A1 (en) Zelatriazin for the treatment of depression
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
TW200528098A (en) Treatment of insomnia in human patients
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
Bello Central nervous system stimulants and drugs that suppress appetite
WO2024196957A1 (en) Method for treating l-dopa-induced dyskinesia using befiradol
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
EA044015B1 (ru) Дейтетрабеназин для лечения дискинезии при церебральном параличе